Literature DB >> 22854535

Adenosine induces apoptosis in SBC-3 human lung cancer cells through A(3) adenosine receptor-dependent AMID upregulation.

Takeshi Kanno1, Takashi Nakano, Yumiko Fujita, Akinobu Gotoh, Tomoyuki Nishizaki.   

Abstract

BACKGROUND/AIMS: We have shown that A(3) adenosine receptor mediates apoptosis in human lung cancer cells such as A549 cells, an epithelial adenocarcinoma cell line, and Lu-65 cells, a giant cell cancer cell line, via each different signaling pathway. AMID, a pro-apoptotic protein, induces caspase-independent apoptosis by accumulating in the nucleus. The present study investigated AMID-dependent apoptosis through A(3) adenosine receptor in SBC-3 cells, a human small cell lung cancer cell line.
METHODS: MTT assay, TUNEL staining, flow cytometry using propidium iodide and annexin V-FITC, and Western blotting were carried out in SBC-3 cells transfected with and without the siRNA to silence the A(3) adenosine receptor-targeted gene or the AMID-targeted gene.
RESULTS: Adenosine induced SBC-3 cell apoptosis in a concentration (0.01-10 mM) and treatment time (24-72 h)-dependent manner, and a similar effect was obtained with the A(3) adenosine receptor agonist 2-Cl-IB-MECA. Adenosine-induced SBC-3 cell death was inhibited by the A(3) adenosine receptor inhibitor MRS1191, knocking-down A(3) adenosine receptor, or knocking-down AMID. Adenosine upregulated expression of the AMID mRNA and protein in SBC-3 cells, that is suppressed by knocking-down A(3) adenosine receptor. In addition, adenosine increased nuclear AMID localization in concert with decreased cytosolic AMID localization.
CONCLUSION: The results of the present study show that adenosine induces SBC-3 cell apoptosis by upregulating AMID expression and promoting AMID translocation into the nucleus via A(3) adenosine receptor.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22854535     DOI: 10.1159/000341447

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  8 in total

Review 1.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

Review 2.  The Purinergic Landscape of Non-Small Cell Lung Cancer.

Authors:  Serena Janho Dit Hreich; Jonathan Benzaquen; Paul Hofman; Valérie Vouret-Craviari
Journal:  Cancers (Basel)       Date:  2022-04-11       Impact factor: 6.575

3.  In vitro effects of a new fused azaisocytosine-like congener on relative cell proliferation, necrosis and cell cycle in cancer and normal cell cultures.

Authors:  Małgorzata Sztanke; Jolanta Rzymowska; Krzysztof Sztanke
Journal:  Mol Cell Biochem       Date:  2016-06-23       Impact factor: 3.396

Review 4.  Immunity, inflammation and cancer: a leading role for adenosine.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Nat Rev Cancer       Date:  2013-11-14       Impact factor: 60.716

Review 5.  Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.

Authors:  Selena Vigano; Dimitrios Alatzoglou; Melita Irving; Christine Ménétrier-Caux; Christophe Caux; Pedro Romero; George Coukos
Journal:  Front Immunol       Date:  2019-06-06       Impact factor: 7.561

Review 6.  Inhibition of the Adenosinergic Pathway in Cancer Rejuvenates Innate and Adaptive Immunity.

Authors:  Juliana Hofstätter Azambuja; Nils Ludwig; Elizandra Braganhol; Theresa L Whiteside
Journal:  Int J Mol Sci       Date:  2019-11-14       Impact factor: 5.923

Review 7.  Purine-Metabolising Enzymes and Apoptosis in Cancer.

Authors:  Marcella Camici; Mercedes Garcia-Gil; Rossana Pesi; Simone Allegrini; Maria Grazia Tozzi
Journal:  Cancers (Basel)       Date:  2019-09-12       Impact factor: 6.639

8.  Host CD39 Deficiency Affects Radiation-Induced Tumor Growth Delay and Aggravates Radiation-Induced Normal Tissue Toxicity.

Authors:  Alina V Meyer; Diana Klein; Simone de Leve; Klaudia Szymonowicz; Martin Stuschke; Simon C Robson; Verena Jendrossek; Florian Wirsdörfer
Journal:  Front Oncol       Date:  2020-10-22       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.